ProCE Banner Activity

CE / CME

Precision in Early-Stage NSCLC Care: ​Community Workshop on the Optimal​ Integration of Biomarker-Driven Therapy

Video

On-demand webcast of expert faculty presentation and case discussion featuring implementation strategies for practicing precision medicine to treat patients with early-stage non-small-cell lung cancer.

(Editor’s Note: This live presentation was recorded on September 29, 2024. On October 3, 2024, the FDA approved nivolumab with platinum-doublet chemotherapy as neoadjuvant therapy, followed by single-agent nivolumab after surgery as adjuvant treatment, for adults with resectable NSCLC [tumors ≥4 cm and/or node positive] and no known EGFR mutations or ALK rearrangements. This approval was based on the results of the CheckMate-77T trial.)

Nurses: 0.75 Nursing contact hour

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Released: October 18, 2024

Expiration: April 17, 2025

Share

Faculty

Karen Reckamp

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director, Clinical Research
Professor, Department of Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC

Merck Sharp & Dohme, LLC

Target Audience

This program is intended for community oncologists, nurses, pharmacists, and other healthcare professionals involved in the diagnosis and management of patients with early-stage non-small cell lung cancer.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, and competence of community oncologists regarding the optimal medical and therapeutic management of patients with early-stage non-small cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate the latest molecular and biomarker testing guidance for the identification of oncogenic drivers in patients with early-stage NSCLC​

  • Determine the most appropriate perioperative treatment strategy that incorporates patient-specific factors and the results obtained from biomarker testing

  • Determine if individual patients with resectable early-stage NSCLC who are candidates for enrollment in an ongoing investigational clinical trial based on the presence of an ALK fusion, and counsel patients on the investigational therapies targeting ALK

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director, Clinical Research
Professor, Department of Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Karen Reckamp, MD, MS: consultant/advisor/speaker: AstraZeneca, Blueprint, Boehringer Ingelheim, Daiichi Sankyo, Genentech, GlaxoSmithKline, Janssen, Lilly, Mirati, Novacure, Novartis; researcher (paid to institution): Blueprint, Daiichi Sankyo, Elevation Oncology, Genentech, Janssen.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 18, 2024, through April 17, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-24-289-H01-P  

Type of Activity: Application 

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.